Knowledge base
Archived articles from Synergus RWE, kept for reference.
12 articles
Real-World data provide essential insights about Myeloma
Characteristics of patients outside typical RCTs: “The overall incidence and median age were both higher than in most previous studies, indicating a more complete coverage of older patients. Myeloma survival in Sweden…
R-RCT from the Obesity registry resolve uncertainty about comparative effectiveness
In the recently published BEST trial(1,2), a Registry-based Randomized Clinical Trial (R-RCT), they answered the uncertainty of comparative efficacy and safety for two surgical interventions. Based on this study,…
Swedish drug registry – Data since 2005 and perfect linkage to other datasets
Sweden established the Prescribed drug registry was established July 2005, covering the whole Swedish population. (1) Through the personal identity number(2) it can be seamlessly linked to other data sets: The more than…
Comparing RWD : Finland vs Sweden
There is rivalry between Finland and Sweden in Sweden in sports. But who has the best Real-World-Data? In a recent webinar about the RWE opportunity in Finland, we included a section where we discussed similarities and…
Swedish Real-World data sources – National registries
Swedish Real-World data sources – National registries This is the first blogpost in a series about the available Real-World Data sets in Sweden focusing on the national registries. Seamless linkage is essential To…
High quality RWE - Registry based randomized clinical trials
There is an increasing need to develop high-quality evidence to support decision makers. There are many important improvements that require such big trials that they are never done. In the recent decade there has been a…
High-quality RWE – Transparency about data quality
The foundation for high-quality RWE is the ability to define the right variables, the ability to collect and finally the ability to transparently report the quality of the data. The ability to succeed with this very…
Mortality and Cause of death variable in Oncology
Context of blog – European Payer perspective While developing this blog, I realized how important it is to clarify the perspective with which you review a certain question. My perspective, even though initially not…
Flatiron vs Sweden – How does the oncology data registers compare?
The potential use of data from Flatiron to support regulatory and reimbursement applications in oncology has stirred up quite an interest in the field. The current developments we have been seeing prove the potential of…
Combination of app-based data collection linked to rich data-sets provides a unique (largely untapped) gold mine
Many have heard that the Nordic Countries have good opportunities for real world evidence studies. From the activity we can observe, it appears that the opportunity is not fully understood by industry. There is a large…
Value based health care – Already here, but still a long journey to connect to payments
In a recent report by the Economist, Sweden was pointed out as the leading country in the world in terms of being prepared for value based health care (VBHC). Click here to see the report. The high quality patient…
Nordic HTA activity
In the below graphs, you can see the HTA activity in the Nordic countries. Particullary interesting to see the increased used of mini-HTA assessments in Norway and Sweden. HTA Update